October 3, 2023

Threshold of Diabetes Diagnosis May Be Too High for Women Under 50

Additional 17 percent of undiagnosed women aged younger than 50 years could be reclassified as having diabetes mellitus. Women aged younger than 50 years have a markedly lower hemoglobin A1c (HbA1c) distribution than men, according to a study published online Sept. 30 in Diabetes Therapy to coincide with the annual meeting of the European Association for the...

Maternal COVID-19 Vaccination Provides Some Protection for Infants

Some protection against COVID-19-related hospitalizations seen among infants, especially those aged younger than 3 months. Maternal COVID-19 vaccination provides some protection against COVID-19-related hospitalization among infants, especially those aged younger than 3 months, according to research published in the Sept. 29 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report....

Inflammatory Bowel Disease Tied to Higher Risk for Gout

Risk for gout even higher in patients with Crohn disease and ulcerative colitis who undergo intestinal resection. Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland Clinic, and colleagues investigated the association between IBD and gout using data from...

Sexual, Gender Minorities With Chronic Skin Diseases More Likely to Face Barriers to Care

Cost and noncost barriers more likely for sexual and gender-minority patients with chronic inflammatory skin diseases Sexual and gender-minority (SGM) patients with chronic inflammatory skin diseases (CISDs) are more likely to experience cost and noncost barriers to care, according to a study published online Sept. 27 in JAMA Dermatology. Michael R. Nock, from the Yale School...

Methotrexate for Cutaneous Cytokine Expression in Refractory Atopic Dermatitis

Methotrexate treatment for refractory adult atopic dermatitis leads to changes in the cutaneous expression of IL-31 and IL-31RA, according to a recent study. Atopic dermatitis (AD) is a chronic skin disease with a complex pathophysiology. AD treatment requires inflammation reduction and skin barrier repair. Therefore, methotrexate (MTX) may serve as a treatment for patients with...

Scratching in Atopic Dermatitis and Brachioradial Pruritus: Neuroanatomy and Sensations

Chronic scratching increases epidermal neuronal branching and sensitivity in patients with atopic dermatitis and brachioradial pruritus, according to a recent study. Persistent and excessive scratching can worsen itch intensity, leading to an itch–scratch cycle. This repetition causes skin barrier impairment and lichenification, characterized by enhanced inflammation and neuropathy.  A study in Frontiers in Molecular Neuroscience...

Non-Alcoholic Fatty Liver Disease Prevalence in Moderate-to-Severe Atopic Dermatitis

A recent study found no significant association between moderate-to-severe atopic dermatitis and the incidence of non-alcoholic fatty liver disease. Atopic dermatitis (AD) is an inflammatory skin disease affecting approximately 20% of children and 2–8% of adults. Some studies have linked AD to metabolic syndrome. As metabolic syndrome is associated with non-alcoholic fatty liver disease (NAFLD),...

Efficacy and Tolerability of Xyloglucan and Pea Protein in Atopic Dermatitis

Topical treatment containing xyloglucan and pea protein was found to be a safe and effective steroid-sparing alternative for children with atopic dermatitis in a recent study. Atopic dermatitis (AD) is a chronic inflammatory skin condition primarily affecting children. Topical corticosteroids are the main treatment used to control skin inflammation and flare-ups in the pediatric population...

Efficacy and Safety of Dupilumab in Children With Severe Atopic Dermatitis

A phase III trial found that long-term dupilumab treatment demonstrated acceptable safety and sustained efficacy in children aged 6–11 years with severe atopic dermatitis. Atopic dermatitis (AD) is the most prevalent inflammatory skin disease in children. Treatment options are limited in children aged 6–11 years with severe AD inadequately controlled by topical therapies. Dupilumab has...
<<
  • 1
  • 2
>>

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.